These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 36609661)

  • 21. Modeling UBQLN2-mediated neurodegenerative disease in mice: Shared and divergent properties of wild type and mutant UBQLN2 in phase separation, subcellular localization, altered proteostasis pathways, and selective cytotoxicity.
    Sharkey LM; Sandoval-Pistorius SS; Moore SJ; Gerson JE; Komlo R; Fischer S; Negron-Rios KY; Crowley EV; Padron F; Patel R; Murphy GG; Paulson HL
    Neurobiol Dis; 2020 Sep; 143():105016. PubMed ID: 32653673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A glutaminyl cyclase-catalyzed α-synuclein modification identified in human synucleinopathies.
    Hartlage-Rübsamen M; Bluhm A; Moceri S; Machner L; Köppen J; Schenk M; Hilbrich I; Holzer M; Weidenfeller M; Richter F; Coras R; Serrano GE; Beach TG; Schilling S; von Hörsten S; Xiang W; Schulze A; Roßner S
    Acta Neuropathol; 2021 Sep; 142(3):399-421. PubMed ID: 34309760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unbiased Proteomics of Early Lewy Body Formation Model Implicates Active Microtubule Affinity-Regulating Kinases (MARKs) in Synucleinopathies.
    Henderson MX; Chung CH; Riddle DM; Zhang B; Gathagan RJ; Seeholzer SH; Trojanowski JQ; Lee VMY
    J Neurosci; 2017 Jun; 37(24):5870-5884. PubMed ID: 28522732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dynamic reversibility of α-synuclein serine-129 phosphorylation is impaired in synucleinopathy models.
    Ramalingam N; Brontesi L; Jin SX; Selkoe DJ; Dettmer U
    EMBO Rep; 2023 Dec; 24(12):e57145. PubMed ID: 37870370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phosphorylated NUB1 distinguishes α-synuclein in Lewy bodies from that in glial cytoplasmic inclusions in multiple system atrophy.
    Tanji K; Miki Y; Mori F; Kon T; Kakita A; Takahashi H; Wakabayashi K
    Brain Pathol; 2019 Nov; 29(6):803-812. PubMed ID: 31006160
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phosphorylation of α-synuclein at T64 results in distinct oligomers and exerts toxicity in models of Parkinson's disease.
    Matsui H; Ito S; Matsui H; Ito J; Gabdulkhaev R; Hirose M; Yamanaka T; Koyama A; Kato T; Tanaka M; Uemura N; Matsui N; Hirokawa S; Yoshihama M; Shimozawa A; Kubo SI; Iwasaki K; Hasegawa M; Takahashi R; Hirai K; Kakita A; Onodera O
    Proc Natl Acad Sci U S A; 2023 Jun; 120(23):e2214652120. PubMed ID: 37252975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AMBRA1, a novel α-synuclein-binding protein, is implicated in the pathogenesis of multiple system atrophy.
    Miki Y; Tanji K; Mori F; Tatara Y; Utsumi J; Sasaki H; Kakita A; Takahashi H; Fimia GM; Wakabayashi K
    Brain Pathol; 2018 Jan; 28(1):28-42. PubMed ID: 27875637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of microRNA deregulation on chaperone-mediated autophagy and α-synuclein pathology in Parkinson's disease.
    Alvarez-Erviti L; Seow Y; Schapira AH; Rodriguez-Oroz MC; Obeso JA; Cooper JM
    Cell Death Dis; 2013 Mar; 4(3):e545. PubMed ID: 23492776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
    Lee VM; Trojanowski JQ
    Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of α- and β-Synucleins in the Axonal Pathology of Parkinson's Disease and Related Synucleinopathies.
    Sekigawa A; Takamatsu Y; Sekiyama K; Hashimoto M
    Biomolecules; 2015 May; 5(2):1000-11. PubMed ID: 25996784
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autophagy in Synucleinopathy: The Overwhelmed and Defective Machinery.
    Arotcarena ML; Teil M; Dehay B
    Cells; 2019 Jun; 8(6):. PubMed ID: 31181865
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2.
    Daher JP; Pletnikova O; Biskup S; Musso A; Gellhaar S; Galter D; Troncoso JC; Lee MK; Dawson TM; Dawson VL; Moore DJ
    Hum Mol Genet; 2012 Jun; 21(11):2420-31. PubMed ID: 22357653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SMG1 identified as a regulator of Parkinson's disease-associated alpha-synuclein through siRNA screening.
    Henderson-Smith A; Chow D; Meechoovet B; Aziz M; Jacobson SA; Shill HA; Sabbagh MN; Caviness JN; Adler CH; Driver-Dunckley ED; Beach TG; Yin H; Dunckley T
    PLoS One; 2013; 8(10):e77711. PubMed ID: 24204929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early and persistent expression of phosphorylated α-synuclein in the enteric nervous system of A53T mutant human α-synuclein transgenic mice.
    Bencsik A; Muselli L; Leboidre M; Lakhdar L; Baron T
    J Neuropathol Exp Neurol; 2014 Dec; 73(12):1144-51. PubMed ID: 25383638
    [TBL] [Abstract][Full Text] [Related]  

  • 35. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
    Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
    Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.
    Wang B; Underwood R; Kamath A; Britain C; McFerrin MB; McLean PJ; Volpicelli-Daley LA; Whitaker RH; Placzek WJ; Becker K; Ma J; Yacoubian TA
    J Neurosci; 2018 Sep; 38(38):8211-8232. PubMed ID: 30093536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. α-Synuclein conformers reveal link to clinical heterogeneity of α-synucleinopathies.
    Schmitz M; Candelise N; Canaslan S; Altmeppen HC; Matschke J; Glatzel M; Younas N; Zafar S; Hermann P; Zerr I
    Transl Neurodegener; 2023 Mar; 12(1):12. PubMed ID: 36915212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein.
    Landeck N; Hall H; Ardah MT; Majbour NK; El-Agnaf OM; Halliday G; Kirik D
    Mol Neurodegener; 2016 Aug; 11(1):61. PubMed ID: 27549140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proteasome inhibition induces α-synuclein SUMOylation and aggregate formation.
    Kim YM; Jang WH; Quezado MM; Oh Y; Chung KC; Junn E; Mouradian MM
    J Neurol Sci; 2011 Aug; 307(1-2):157-61. PubMed ID: 21641618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. G protein-coupled receptor kinase 5, overexpressed in the alpha-synuclein up-regulation model of Parkinson's disease, regulates bcl-2 expression.
    Liu P; Wang X; Gao N; Zhu H; Dai X; Xu Y; Ma C; Huang L; Liu Y; Qin C
    Brain Res; 2010 Jan; 1307():134-41. PubMed ID: 19852948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.